Primus Reports
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-Jul-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Finance Minister Announces “Green Bonds” to Mobilise Resources for Green Infrastructure; Experts Welcome Move
- Interim Budget 2024: Textile and apparel industry seeks tax incentives, infra boost for growth
- Immunity Products, Tele-Medicine, Household Gadgets Driving Consumer Demand In Covid Times: ASSOCHAM-PRIMUS Report
- Union budget 2024: FM Sitharaman announces three schemes to boost employment